KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Cost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsInterest & Investment IncomeInterest ExpensesNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Travere Therapeutics (TVTX) Shares Outstanding (Diluted Average) (2016 - 2025)

Historic Shares Outstanding (Diluted Average) for Travere Therapeutics (TVTX) over the last 13 years, with Q3 2025 value amounting to $102.6 million.

  • Travere Therapeutics' Shares Outstanding (Diluted Average) rose 3193.54% to $102.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $102.6 million, marking a year-over-year increase of 3193.54%. This contributed to the annual value of $78.9 million for FY2024, which is 622.27% up from last year.
  • Per Travere Therapeutics' latest filing, its Shares Outstanding (Diluted Average) stood at $102.6 million for Q3 2025, which was up 3193.54% from $88.9 million recorded in Q2 2025.
  • Travere Therapeutics' 5-year Shares Outstanding (Diluted Average) high stood at $102.6 million for Q3 2025, and its period low was $56.3 million during Q1 2021.
  • For the 5-year period, Travere Therapeutics' Shares Outstanding (Diluted Average) averaged around $72.5 million, with its median value being $74.3 million (2023).
  • Its Shares Outstanding (Diluted Average) has fluctuated over the past 5 years, first skyrocketed by 3531.29% in 2021, then soared by 193.14% in 2024.
  • Quarter analysis of 5 years shows Travere Therapeutics' Shares Outstanding (Diluted Average) stood at $59.8 million in 2021, then grew by 6.56% to $63.8 million in 2022, then increased by 16.48% to $74.3 million in 2023, then increased by 6.22% to $78.9 million in 2024, then surged by 30.08% to $102.6 million in 2025.
  • Its Shares Outstanding (Diluted Average) was $102.6 million in Q3 2025, compared to $88.9 million in Q2 2025 and $88.4 million in Q1 2025.